AstraZeneca's Koselugo Approved in US
Ticker: AZN · Form: 6-K · Filed: Nov 20, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, oncology, new-drug
TL;DR
AstraZeneca's cancer drug Koselugo just got US approval!
AI Summary
AstraZeneca PLC announced on November 20, 2025, that Koselugo (selumeticinib) has been approved in the US. This marks a significant milestone for the company's oncology portfolio.
Why It Matters
The US approval of Koselugo represents a new treatment option for patients and expands AstraZeneca's presence in the oncology market.
Risk Assessment
Risk Level: low — This is a routine filing announcing a regulatory approval, which is generally positive news.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- Koselugo (selumeticinib) (drug) — Drug that received US approval
- 20251120 (date) — Filing date
FAQ
What is the specific indication for Koselugo's US approval?
The filing does not specify the exact indication for Koselugo's US approval, but it is related to AstraZeneca's oncology portfolio.
When was this report filed with the SEC?
This report was filed on November 20, 2025.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Issuer filed to announce the US approval of Koselugo (selumeticinib).
What is AstraZeneca's primary business sector?
AstraZeneca PLC is in the Pharmaceutical Preparations sector, SIC code 2834.
Does AstraZeneca file annual reports under Form 20-F or 40-F?
AstraZeneca indicates it files annual reports under cover of Form 20-F.
Filing Stats: 1,724 words · 7 min read · ~6 pages · Grade level 13.8 · Accepted 2025-11-20 08:31:49
Filing Documents
- a2653i.htm (6-K) — 40KB
- 0001654954-25-013317.txt ( ) — 41KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 20 November 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary